PHARMACOKINETICS, EFFICACY AND SAFETY OF MIRIKIZUMAB AS INDUCTION THERAPY IN PAEDIATRIC PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: RESULTS FROM THE PHASE 2 SHINE-1 STUDY

Jess L. Kaplan  1     Athos Bousvaros  2     Dan Turner  3     Marla C. Dubinsky  4     Wendy Komocsar  5     Amy Larkin  5     Jordan Johns  5     Xin Zhang  5     Cheryl Little  5     Wallace Crandall  5     Vipin Arora  5     Jeffrey Hyams  6    
1 Mass General for Children, Boston, United States
2 Boston Children’s Hospital, Boston, United States
3 Shaare Zedek Medical Center, Jerusalem, Israel
4 Mount Sinai Hospital, New York, United States
5 Eli Lilly and Company, Indianapolis, United States
6 Connecticut Children’s Medical Center, Hartford, United States

Topic
IBD

Conference
UEG Week 2023

Citation
United European Gastroenterology Journal 2023; 11 (Supplement 8)


Login to access library content

Login

Do you need help setting up your myUEG account?
Contact us at [email protected]

New to myUEG?

Create myUEG account

Social Sharing